logo
  

Versus Systems Secures Investment From Cronus Equity Capital; Stock Up

Versus Systems Inc. (VS) said that it secured a strategic investment from Cronus Equity Capital Group LLC or "CECG".

The Investment contemplates the issuance of up to about 24.73 million common shares of Versus to CECG representing about 51% of the company's issued and outstanding common shares of which 15.84 million common shares or the "First Tranche were issued to CECG on November 22, 2023 and a further 8.89 million common shares or the "Second Tranche" are expected to be issued to CECG next week.

As per the terms of the deal, CECG purchased the First Tranche at a price of $0.1618 per share, representing a premium to the five-day average Nasdaq Official Closing Price of $0.1578 per share, for a total $2.56 million. The Second Tranche will be completed at the same price per share.

There were no warrants in the transaction.

In Friday pre-market trade, VS was trading at $0.25 up $0.09 or 50.60%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft has launched a new category of Windows PCs designed for Artificial Intelligence (AI) that are slated to be the fastest and most intelligent Windows PCs ever built. The Copilot+ PCs come with built-in AI hardware and will support AI features across the operating system. Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings...

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT